GLP-1 Medications and Hashimoto's Thyroiditis: What the Research Shows

If you have Hashimoto's thyroiditis and have been struggling with weight loss that doesn't respond the way it should, new research on GLP-1 medications and Hashimoto's thyroiditis offers some useful context.

*Compounded semaglutide and compounded tirzepatide are not FDA-approved medications. This article is for educational and informational purposes only and does not constitute medical advice. Clinical research cited here was conducted using FDA-approved pharmaceutical formulations unless otherwise noted. If you have Hashimoto's thyroiditis, hypothyroidism, or any thyroid condition, consult your prescribing physician or endocrinologist before starting, stopping, or adjusting any medication. Individual results vary. All prescribing at Prescriva is performed by independently licensed healthcare providers.*

---

If you have Hashimoto's thyroiditis and have been trying to lose weight, you already know that standard advice - eat less, move more - often falls short. Your metabolism does not work the way a textbook describes. Your energy is inconsistent. Your body seems to hold onto weight even when you are doing everything right.

That experience is not a motivation problem. It reflects real physiological differences in how autoimmune thyroid disease affects your metabolism, hormones, and appetite regulation. And as GLP-1 receptor agonist medications like semaglutide and tirzepatide have become more widely used for weight management, researchers have begun asking an important question: what happens when people with Hashimoto's thyroiditis use these medications?

The answer is still unfolding, but the emerging picture is worth understanding before you talk to your provider.

---

What Is Hashimoto's Thyroiditis?

Hashimoto's thyroiditis is an autoimmune condition in which your immune system mistakenly attacks thyroid tissue. Over time, this damages the thyroid gland's ability to produce thyroid hormone, leading to hypothyroidism.

It is the most common cause of hypothyroidism in the United States. The American Thyroid Association estimates it affects around 14 million Americans, with women accounting for roughly 90 percent of cases. Many people are diagnosed in their 30s and 40s, often after years of unexplained symptoms: fatigue, brain fog, cold intolerance, hair thinning, constipation, and difficulty losing weight despite appropriate caloric restriction.

The autoimmune component matters here. Hashimoto's is not simply a thyroid hormone deficiency - it is an ongoing inflammatory process. Immune cells infiltrate thyroid tissue, and the resulting inflammation is systemic enough that it affects metabolism, gut motility, insulin sensitivity, and how the brain processes hunger signals. All of these systems also happen to be ones that GLP-1 medications are known to influence.

---

Lower Natural GLP-1 Levels in Hashimoto's Patients

One finding from the research may surprise you. Researchers measured natural (endogenous) GLP-1 levels in people with Hashimoto's thyroiditis and found they were significantly lower than in healthy controls without the condition [1].

GLP-1 - glucagon-like peptide-1 - is a hormone your gut produces naturally after meals. It tells your brain you are full, slows how quickly your stomach empties, and helps regulate blood sugar by stimulating insulin release. When your natural GLP-1 levels are lower, these signals may be weaker. You may feel hungry sooner after eating. Satiety signals may not register as strongly.

This is not a proven causal chain, and the research is early. But it raises a meaningful question: if people with Hashimoto's thyroiditis have suppressed natural GLP-1 signaling, could GLP-1 receptor agonist medications help restore more normal appetite regulation? That is exactly what researchers have been trying to understand.

---

Can GLP-1 Medications Support Weight Loss in Hypothyroidism?

A 2025 retrospective study published in PLoS One examined weight and body composition outcomes specifically in people with well-treated hypothyroidism who used liraglutide - a GLP-1 receptor agonist - for weight management [2].

The participants had stable thyroid function on levothyroxine before starting liraglutide. Researchers tracked changes in body weight, fat mass, lean mass, and metabolic markers over the treatment period.

The results suggested that people with well-controlled hypothyroidism can achieve meaningful weight loss on GLP-1 medications, comparable to outcomes in people without thyroid disease. This is clinically significant because many providers and patients wonder whether thyroid dysfunction limits the effectiveness of weight management treatments.

The study's retrospective design limits how definitive its conclusions can be. But it provides early clinical evidence that hypothyroidism, when treated and stable, does not appear to be a barrier to GLP-1 medication effectiveness.

---

What Happens to Your TSH When You Start a GLP-1 Medication?

This is one of the most practically important questions for anyone on levothyroxine who is considering a GLP-1 medication - and a 2026 study in the Journal of Clinical Endocrinology and Metabolism addressed it directly [3].

Researchers used a trial emulation approach to examine patterns in TSH (thyroid-stimulating hormone) testing and results in patients on stable levothyroxine who then started a GLP-1 receptor agonist. TSH is the primary measure of thyroid hormone balance. When TSH rises above the normal range, it signals that levothyroxine may not be fully compensating, and your thyroid may need more support.

The study found that some patients on levothyroxine showed changes in their TSH levels after starting a GLP-1 medication. This is likely related to how GLP-1 medications affect gastric emptying and gut motility. When your stomach empties more slowly, it can change how and when levothyroxine absorbs into your bloodstream - potentially reducing the effective dose you receive from the same tablet.

The clinical implication is clear: if you are on levothyroxine and start a GLP-1 medication, your provider should monitor your TSH more closely, especially in the first three to six months. A levothyroxine dose adjustment may be needed.

---

The Anti-Inflammatory Angle: Still Early, But Worth Watching

Hashimoto's thyroiditis is, at its core, an inflammatory autoimmune condition. The immune attack on the thyroid gland is driven by the same kinds of inflammatory cytokines that GLP-1 medications appear to modulate in other conditions.

A 2025 Cureus review examined the growing body of evidence on GLP-1 receptor agonists and autoimmune thyroid disease, noting that GLP-1 has measurable anti-inflammatory properties that extend beyond blood sugar and weight management [4]. The review highlighted animal studies showing GLP-1 receptor activation can reduce thyroid gland inflammation. Human data is more limited, but early observations from patients using GLP-1 medications have noted changes in autoimmune markers in some individuals.

This does not mean GLP-1 medications are a treatment for Hashimoto's thyroiditis. They are not, and they are not prescribed for that purpose. But the anti-inflammatory activity of GLP-1 may be relevant to how these medications behave in people who have the condition.

What that means practically: if you have Hashimoto's and also have obesity or significant metabolic dysfunction, the anti-inflammatory effects of GLP-1 medications could offer value beyond weight management - though this remains an active area of research rather than established clinical guidance.

---

Semaglutide vs. Tirzepatide: Any Differences for Thyroid Conditions?

Both semaglutide and tirzepatide are GLP-1 receptor agonists, but tirzepatide adds a second mechanism: it also activates GIP (glucose-dependent insulinotropic polypeptide) receptors. For thyroid conditions, the practical considerations are largely similar, but a 2026 review in Clinical Obesity addressed tirzepatide's thyroid profile specifically [5].

The review noted that for people with pre-existing thyroid disease on stable thyroid hormone replacement therapy, tirzepatide appears to be safe, but recommended monitoring TSH after initiating treatment given tirzepatide's potent effects on gastric motility and GI absorption. A 2026 case report in Cureus described a patient who had undergone prior thyroid surgery and experienced levothyroxine absorption changes after starting tirzepatide, requiring dose recalibration [6].

A separate 2026 case report described a patient with Hashimoto's thyroiditis who developed transient hyperprolactinemia after starting semaglutide [7]. The condition resolved after stopping the medication. The authors noted this as a rare interaction and flagged it as something clinicians should be aware of in patients with pre-existing autoimmune thyroid disease.

These cases do not mean either medication is contraindicated in Hashimoto's. They do underscore that people with thyroid disease starting GLP-1 medications deserve more careful monitoring than the general population.

---

A Note on Thyroid Cancer Risk: What You May Have Heard

You may have seen warnings about thyroid cancer risk and GLP-1 medications. It is worth clarifying what that concern is about, because it is different from Hashimoto's thyroiditis.

GLP-1 receptor agonists carry a boxed warning from the FDA regarding medullary thyroid carcinoma (MTC), a rare cancer that originates in the C-cells of the thyroid gland. This concern comes from rodent studies showing GLP-1 receptor activation in C-cells at high doses. Importantly, this risk is specifically about MTC and its precursor, multiple endocrine neoplasia type 2 (MEN2).

Hashimoto's thyroiditis is a disease of thyroid follicular cells, not C-cells. It is an autoimmune condition, not a cancer. Having Hashimoto's does not place you in the high-risk category for GLP-1-related thyroid cancer concerns, and the FDA's boxed warning does not apply differently based on whether you have Hashimoto's.

That said, if you have a personal or family history of MTC or MEN2, GLP-1 medications are contraindicated. Always discuss your personal thyroid history with your prescribing provider before starting any GLP-1 medication.

---

What to Discuss With Your Healthcare Provider

If you have Hashimoto's thyroiditis and are considering a GLP-1 medication for weight management, these are the key clinical points to raise with your provider:

TSH monitoring schedule. Ask for a TSH test before starting the medication to establish a baseline, and plan to retest at three months and six months after initiating treatment. If your TSH changes significantly, your levothyroxine dose may need adjustment.

Levothyroxine timing and absorption. GLP-1 medications slow gastric emptying. Some providers recommend taking levothyroxine at a consistent time each day and waiting 30 to 60 minutes before eating or taking other medications, as they always should. Given that GLP-1 medications further alter gut motility, this timing discipline becomes even more important.

Your anti-TPO and anti-Tg antibody levels. If your Hashimoto's is active and your antibody levels are high, ask your provider whether baseline antibody testing makes sense before starting a GLP-1 medication, so any changes can be tracked over time.

Your current thyroid stability. The research suggests GLP-1 medications can be effective in people with hypothyroidism when it is well-managed. If your TSH is stable and your levothyroxine dose has been consistent for at least three to six months, you are likely in a better position to start than if your thyroid function is currently fluctuating.

Side effects and their overlap with Hashimoto's symptoms. GLP-1 medications commonly cause nausea, fatigue, and constipation, especially early in treatment. These symptoms can overlap with undertreated hypothyroidism. If you experience these side effects after starting a GLP-1 medication, it is worth checking your TSH to ensure your levothyroxine dose is still appropriate before attributing everything to the new medication.

---

Key Takeaways

People with Hashimoto's thyroiditis face real metabolic challenges that make weight loss harder, and new research is beginning to map how GLP-1 medications interact with this condition.

The early evidence suggests:

• Natural GLP-1 levels may be lower in people with Hashimoto's, which could partially explain weight management difficulties [1]
• Clinical data supports that GLP-1 medications can produce meaningful weight loss in people with well-treated hypothyroidism [2]
• GLP-1 medications may affect levothyroxine absorption, making TSH monitoring important after starting treatment [3]
• Anti-inflammatory properties of GLP-1 medications may have relevance to autoimmune thyroid disease, though this is early-stage research [4]
• Both semaglutide and tirzepatide require closer monitoring for people on thyroid hormone replacement therapy [5, 6]

This is an evolving area of research. The studies referenced here use FDA-approved semaglutide and liraglutide formulations - the evidence cannot be directly applied to compounded medications, which have not undergone clinical trials. Any decision to start a GLP-1 medication should involve your prescribing physician and, ideally, your endocrinologist if you have complex thyroid disease.

*This is not medical advice. Consult your healthcare provider before making any changes to your medications or treatment plan.*

---

Ready to explore your options? [Check your eligibility](/eligibility) for Prescriva's medically supervised weight management program, where licensed providers review your full medical history before recommending any treatment.

---

References

1. Jin Y, et al. Serum levels of glucagon-like peptide (GLP)-1 and GLP-2 in patients with Hashimoto's thyroiditis. *Journal of Research in Medical Sciences*. 2015;20(2):139-143. PMID: [25983772](https://pubmed.ncbi.nlm.nih.gov/25983772/)

1. Chukir T, et al. Weight and body composition outcomes with liraglutide in individuals with well-treated hypothyroidism: A retrospective cohort study. *PLoS One*. 2025. PMID: [40934243](https://pubmed.ncbi.nlm.nih.gov/40934243/)

1. Chen Y, et al. Patterns of Thyroid-Stimulating Hormone Test After GLP-1 RAs Initiation in Patients on Levothyroxine: A Trial Emulation Study. *Journal of Clinical Endocrinology and Metabolism*. 2026 Mar 27. PMID: [41902399](https://pubmed.ncbi.nlm.nih.gov/41902399/)

1. Mazza AD. The Thyroid Twist: How GLP-1 Agonists Are Influencing Autoimmune Thyroid Care. *Cureus*. 2025 Nov. PMID: [41479489](https://pubmed.ncbi.nlm.nih.gov/41479489/)

1. Manueli Laos EG, et al. Impact of Tirzepatide Therapy on Thyroid Disease: Understanding Risks and Emerging Insights. *Clinical Obesity*. 2026 Jun. PMID: [42145153](https://pubmed.ncbi.nlm.nih.gov/42145153/)

1. Adams EW, et al. Thyroid Dysfunction Following Tirzepatide Use in a Post-thyroidectomy Patient on Stable Levothyroxine Therapy: A Case Study. *Cureus*. 2026 Apr. PMID: [42109981](https://pubmed.ncbi.nlm.nih.gov/42109981/)

1. Guimarães GNF, et al. Transient Hyperprolactinemia Associated With Semaglutide in a Patient With Hashimoto's Thyroiditis. *Case Reports in Medicine*. 2026. PMID: [42211780](https://pubmed.ncbi.nlm.nih.gov/42211780/)